Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.37 |
| ▸ | ACACA | Q13085 | 6/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 9/20 | 0.33 |
| ▸ | CASP3 | P42574 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 3/20 | 0.33 |
| ▸ | CASP7 | P55210 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169966 | 0.87 | ACACB (0.36) | ACACBACACAMAPK7CASP3CDK9 | |
| SCHEMBL10170074 | 0.86 | ACACB (0.38) | ACACBACACAMAPK7CASP3CDK9 | |
| SCHEMBL10170081 | 0.84 | CDK9 (0.37) | ACACBACACAMAPK7CASP3CDK9 | |
| SCHEMBL10170077 | 0.79 | ACACB (0.42) | ACACBACACA | |
| SCHEMBL1816354 | 0.77 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL551053 | 0.77 | ACACB (0.50) | ACACBACACALMNA | |
| SCHEMBL10170052 | 0.77 | KMT2A (0.45) | ACACBACACA | |
| SCHEMBL1812751 | 0.76 | ACACB (0.42) | ACACBACACA | |
| SCHEMBL10169967 | 0.75 | ACACB (0.35) | ACACBACACAMAPK7CASP3CDK9 | |
| SCHEMBL1813091 | 0.73 | ACACB (0.46) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | ACACA, ACAT1, ACACB | ACACB 3/4885ACACA 1/4885MAPK7 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.